<?xml version="1.0" encoding="utf-8" standalone="no"?>
<billStatus>
  <version>3.0.0</version>
  <bill>
    <number>4398</number>
    <updateDate>2022-11-01T13:49:55Z</updateDate>
    <updateDateIncludingText>2022-11-01T13:49:55Z</updateDateIncludingText>
    <originChamber>House</originChamber>
    <type>HR</type>
    <introducedDate>2019-09-19</introducedDate>
    <congress>116</congress>
    <constitutionalAuthorityStatementText><![CDATA[<pre>[Congressional Record Volume 165, Number 151 (Thursday, September 19, 2019)][House]From the Congressional Record Online through the Government Publishing Office [<a href="http://www.gpo.gov">www.gpo.gov</a>]By Mr. CICILLINE:H.R. 4398.Congress has the power to enact this legislation pursuantto the following:Article 1 Section 8[Page H7836]</pre>]]></constitutionalAuthorityStatementText>
    <committees>
      <item>
        <systemCode>hsju00</systemCode>
        <name>Judiciary Committee</name>
        <chamber>House</chamber>
        <type>Standing</type>
        <subcommittees>
          <item>
            <systemCode>hsju05</systemCode>
            <name>Administrative State, Regulatory Reform, and Antitrust Subcommittee</name>
            <activities>
              <item>
                <name>Referred to</name>
                <date>2019-10-02T20:08:11Z</date>
              </item>
            </activities>
          </item>
        </subcommittees>
        <activities>
          <item>
            <name>Referred to</name>
            <date>2019-09-19T14:00:22Z</date>
          </item>
        </activities>
      </item>
    </committees>
    <relatedBills>
      <item>
        <title>Affordable Prescriptions for Patients Through Promoting Competition Act of 2019</title>
        <congress>116</congress>
        <number>5133</number>
        <type>HR</type>
        <latestAction>
          <actionDate>2020-12-24</actionDate>
          <text>Placed on the Union Calendar, Calendar No. 578.</text>
        </latestAction>
        <relationshipDetails>
          <item>
            <type>Related bill</type>
            <identifiedBy>CRS</identifiedBy>
          </item>
        </relationshipDetails>
      </item>
      <item>
        <title>Affordable Prescriptions for Patients Act of 2019</title>
        <congress>116</congress>
        <number>1416</number>
        <type>S</type>
        <latestAction>
          <actionDate>2019-06-28</actionDate>
          <text>Placed on Senate Legislative Calendar under General Orders. Calendar No. 132.</text>
        </latestAction>
        <relationshipDetails>
          <item>
            <type>Related bill</type>
            <identifiedBy>CRS</identifiedBy>
          </item>
        </relationshipDetails>
      </item>
      <item>
        <title>Fostering Undergraduate Talent by Unlocking Resources for Education Act</title>
        <congress>116</congress>
        <number>2486</number>
        <type>HR</type>
        <latestAction>
          <actionDate>2020-07-23</actionDate>
          <text>Message on House action received in Senate and at desk: House amendments to Senate amendment.</text>
        </latestAction>
        <relationshipDetails>
          <item>
            <type>Related bill</type>
            <identifiedBy>CRS</identifiedBy>
          </item>
        </relationshipDetails>
      </item>
    </relatedBills>
    <actions>
      <item>
        <actionDate>2019-10-02</actionDate>
        <committees>
          <item>
            <systemCode>hsju05</systemCode>
            <name>Administrative State, Regulatory Reform, and Antitrust Subcommittee</name>
          </item>
        </committees>
        <sourceSystem>
          <code>1</code>
          <name>House committee actions</name>
        </sourceSystem>
        <text>Referred to the Subcommittee on Antitrust, Commercial, and Administrative Law.</text>
        <type>Committee</type>
      </item>
      <item>
        <actionDate>2019-09-19</actionDate>
        <text>Referred to the House Committee on the Judiciary.</text>
        <type>IntroReferral</type>
        <actionCode>H11100</actionCode>
        <sourceSystem>
          <code>2</code>
          <name>House floor actions</name>
        </sourceSystem>
        <committees>
          <item>
            <systemCode>hsju00</systemCode>
            <name>Judiciary Committee</name>
          </item>
        </committees>
      </item>
      <item>
        <actionDate>2019-09-19</actionDate>
        <text>Introduced in House</text>
        <type>IntroReferral</type>
        <actionCode>Intro-H</actionCode>
        <sourceSystem>
          <code>9</code>
          <name>Library of Congress</name>
        </sourceSystem>
      </item>
      <item>
        <actionDate>2019-09-19</actionDate>
        <text>Introduced in House</text>
        <type>IntroReferral</type>
        <actionCode>1000</actionCode>
        <sourceSystem>
          <code>9</code>
          <name>Library of Congress</name>
        </sourceSystem>
      </item>
    </actions>
    <sponsors>
      <item>
        <bioguideId>C001084</bioguideId>
        <fullName>Rep. Cicilline, David N. [D-RI-1]</fullName>
        <firstName>David</firstName>
        <lastName>Cicilline</lastName>
        <party>D</party>
        <state>RI</state>
        <middleName>N.</middleName>
        <district>1</district>
        <isByRequest>N</isByRequest>
      </item>
    </sponsors>
    <policyArea>
      <name>Commerce</name>
    </policyArea>
    <subjects>
      <legislativeSubjects>
        <item>
          <name>Administrative remedies</name>
        </item>
        <item>
          <name>Civil actions and liability</name>
        </item>
        <item>
          <name>Competition and antitrust</name>
        </item>
        <item>
          <name>Consumer affairs</name>
        </item>
        <item>
          <name>Drug safety, medical device, and laboratory regulation</name>
        </item>
        <item>
          <name>Federal Trade Commission (FTC)</name>
        </item>
        <item>
          <name>Health care costs and insurance</name>
        </item>
        <item>
          <name>Inflation and prices</name>
        </item>
        <item>
          <name>Intellectual property</name>
        </item>
        <item>
          <name>Judicial review and appeals</name>
        </item>
        <item>
          <name>Manufacturing</name>
        </item>
        <item>
          <name>Prescription drugs</name>
        </item>
      </legislativeSubjects>
      <policyArea>
        <name>Commerce</name>
      </policyArea>
    </subjects>
    <summaries>
      <summary>
        <versionCode>00</versionCode>
        <actionDate>2019-09-19</actionDate>
        <actionDesc>Introduced in House</actionDesc>
        <updateDate>2021-03-19T15:09:12Z</updateDate>
        <text><![CDATA[ <p><b>Affordable Prescriptions for Patients Through Promoting Competition Act of 2019</b><br> <br> This bill prohibits product hopping by drug manufacturers. Product hopping is presumed when a drug manufacturer engages is a <i>hard switch</i> or a <i>soft switch</i>. A hard switch occurs when, after a manufacturer receives notice of an application for a generic drugs, either, (1) the manufacturer obtains removal of a drug from the Food and Drug Administration&rsquo;s approved drug list or the drug is moved to the discontinued products list, and the manufacturer markets or sells a follow-on product; or (2) a manufacturer announces the withdrawal or discontinuance of a listed drug, or the manufacturer destroys the inventory of a listed drug in a manner that impedes generic drug competitors, and the manufacturer markets or sells a follow-on product. A<i> follow-on product </i>is a changed, modified, or reformulated version of a manufacturer&rsquo;s already-approved drug or biological product that still treats the same medical condition.<br> <br> A soft switch occurs when a manufacturer receives notice of an application for a generic drugs, takes other actions that impede generic drug competitors, and the manufacturer markets or sells a follow-on product.<br> <br> A drug manufacturer may rebut a presumption of product hopping by demonstrating that its conduct was not intended to limit competition.<br> </p>]]></text>
      </summary>
    </summaries>
    <title>Affordable Prescriptions for Patients Through Promoting Competition Act of 2019</title>
    <titles>
      <item>
        <titleType>Display Title</titleType>
        <title>Affordable Prescriptions for Patients Through Promoting Competition Act of 2019</title>
      </item>
      <item>
        <titleType>Official Title as Introduced</titleType>
        <title>To amend the Federal Trade Commission Act to prohibit anticompetitive behaviors by drug product manufacturers, and for other purposes.</title>
        <billTextVersionName>Introduced in House</billTextVersionName>
        <billTextVersionCode>IH</billTextVersionCode>
      </item>
      <item>
        <titleType>Short Title(s) as Introduced</titleType>
        <title>Affordable Prescriptions for Patients Through Promoting Competition Act of 2019</title>
        <billTextVersionName>Introduced in House</billTextVersionName>
        <billTextVersionCode>IH</billTextVersionCode>
      </item>
    </titles>
    <textVersions>
      <item>
        <type>Introduced in House</type>
        <date>2019-09-19T04:00:00Z</date>
        <formats>
          <item>
            <url>https://www.govinfo.gov/content/pkg/BILLS-116hr4398ih/xml/BILLS-116hr4398ih.xml</url>
          </item>
        </formats>
      </item>
    </textVersions>
    <latestAction>
      <actionDate>2019-10-02</actionDate>
      <text>Referred to the Subcommittee on Antitrust, Commercial, and Administrative Law.</text>
    </latestAction>
  </bill>
  <dublinCore xmlns:dc="http://purl.org/dc/elements/1.1/">
    <dc:format>text/xml</dc:format>
    <dc:language>EN</dc:language>
    <dc:rights>Pursuant to Title 17 Section 105 of the United States Code, this file is not subject to copyright protection and is in the public domain.</dc:rights>
    <dc:contributor>Congressional Research Service, Library of Congress</dc:contributor>
    <dc:description>This file contains bill summaries and statuses for federal legislation. A bill summary describes the most significant provisions of a piece of legislation and details the effects the legislative text may have on current law and federal programs. Bill summaries are authored by the Congressional Research Service (CRS) of the Library of Congress. As stated in Public Law 91-510 (2 USC 166 (d)(6)), one of the duties of CRS is "to prepare summaries and digests of bills and resolutions of a public general nature introduced in the Senate or House of Representatives". For more information, refer to the User Guide that accompanies this file.</dc:description>
  </dublinCore>
</billStatus>
